HOME >> BIOLOGY >> NEWS
Consume less trans fat, more vitamin B6 and B12, studies suggest

CHAMPAIGN, Ill. -- The pastries, pizza, potato chips, french fries, margarine, cookies, crackers and bread that Americans consume by the millions of tons contain trans fat (hydrogenated oils). Most of these foods are made with flours deficient in vitamins B6 and B12 and magnesium. The combination of the fat along with the vitamin and mineral deficiency is partly responsible for the formation of calcified ridges that can block the flow of blood in arteries, scientists report.

So what should people do? Eat less trans fat and more foods rich in magnesium, B6 and B12, says Fred A. Kummerow, professor emeritus of food chemistry at the University of Illinois. But it's not that simple: "People can't easily lower their trans fatty acids intake, because they can't tell how much they are getting by looking at labels," Kummerow said. "Some products in Canada list percentages voluntarily, but U.S. food-makers do not, nor are they required to do so by the Food and Drug Administration."

Kummerow is the lead investigator of a study published in the November issue of the American Journal of Clinical Nutrition. Using cultured endothelial cells, his U. of I. team showed that calcification is related to the amount of trans fat, but that it can be mitigated with adequate magnesium levels. The researchers also tested other fatty acids, but did not find similar results.

"This paper shows us under what conditions trans fatty acids are a risk factor to the calcification of coronary arteries, which is the beginning of atherosclerosis, and if you translate this to the human diet, it means that adequate magnesium may modify the formation of calcified streaks," Kummerow said.

In addition to requiring food-makers to list the amount of trans fatty acid in their products, flour producers should be required to include B6 and B12 in their mixes, Kummerow said. Both vitamins prevent high homocysteine blood levels, another recently discovered risk factor in heart dis
'"/>

Contact: Jim Barlow, Life Sciences Editor
b-james3@uiuc.edu
217-333-5802
University of Illinois at Urbana-Champaign
1-Nov-1999


Page: 1 2

Related biology news :

1. Consumer education and development of bio-sensitive alternatives can revive the plastics industry
2. Consumerism, e-commerce and biotechnology to cause changes in health system over next decade, says PricewaterhouseCoopers study
3. Consumers, health experts desire benefits of biotech foods and concur with current FDA labeling policy
4. Researchers, Regulators, Industry, Consumer Advocates Gather to Discuss Critical Issues Facing the Pharmaceutical Industry
5. Emu Meat Not A Popular Choice Among Consumers, Study Shows
6. Americans Urged To Consume More Folic Acid
7. Formaldehyde Emissions From Consumer Products
8. Consumer-Oriented Environmental Policy Unsuccessful
9. IFT Report Describes Challenges Of Food Industry Stepping Up To The P(a)lates Of Consumers
10. Early Tests Indicate Motor Skills Unharmed In Consumers Of Tainted Fish
11. Veterinary Memorial Fund transforms grief into promise

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Consume less trans fat more vitamin and studies suggest

(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... 2015 Veolia’s environmental monitoring technology ... American distribution agreement with VWR to distribute TECTA™ ... more than 160 years of experience, VWR, a ... laboratory and production facilities, has cultivated a value ... services to enable science. Endetec’s TECTA™ B16, ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 This ... history, especially for lawns. US Patented Pearl’s Premium ... for lawns around the country that are coming out ... that addresses a number of major global concerns related ... the “non-grass” grass – the alternative to the standard, ...
(Date:5/20/2015)... -- Health eCareers, the healthcare industry,s online career hub, ... looking for the flexibility of short-term assignments through ... tool dedicated exclusively to temporary and shift work ... employers to quickly find and hire experienced professionals ... other temporary positions, eliminating the time and resources ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
Cached News: